Teleflex Incorporated Tuesday announced that it has received 510(k) market clearance from the U.S. Food and Drug Administration for the company’s ArrowEVOLUTION PICC with Chlorag+ard technology, a peripherally inserted central catheter with a Chlorhexedine-based solution that has been chemically-bonded into the surface of the catheter both intra- and extralumenally.
CNBC